– USA, VA – ReAlta Life Sciences, Inc. today announced that Ulrich Thienel MD, PhD, has been appointed by the Board of Directors as CEO, effective September 1, 2019. In this capacity, Ulrich will provide strategic leadership for commercialization of ReAlta’s new class of Complement and Inflammation Inhibition drug products for a variety of life-threatening medical conditions.
John Harding, Board Chairman said: “The entire Board and Management team of ReAlta are excited to be working with Ulrich in his new role as CEO. Ulrich and his team at RRD International helped ReAlta choose the best initial indications for the company to develop. Ulrich then joined the ReAlta Board following its formation in 2018. His leadership and insights will be invaluable in helping ReAlta to develop our platform of life-saving pharma products.”
About Dr Ulrich Thienel
Ulrich was formerly Chief Medical Officer at Finch Therapeutics, Boston. Prior to Finch, Ulrich had 20 years of biopharmaceutical drug development leadership, with experience in both biotech and large pharma, including Johnson & Johnson, BMS, and Takeda. His experience spans autoimmune, hematology, respiratory and rare diseases. In previous roles as Therapeutic Area Leader and Chief of Development and Medical Officer, he oversaw research development and commercialization of multiple assets, including small molecules, siRNA, antibody and device technologies. He is well versed in FDA regulatory processes, including experience with multiple Investigational New Drugs, New Drug Applications and Biologics License Applications.
Ulrich received his MD and PhD degrees at Justus-Liebig University in Giessen, Germany and also completed training in Internal Medicine. He subsequently completed specialty training in Rheumatology at Columbia University in New York and Executive Training in Sales and Marketing at Northwestern University in Chicago.
About ReAlta Life Sciences, Inc.
ReAlta Life Sciences, Inc. is an early-stage pharmaceutical company incorporated in late, 2018, and located in Norfolk, Virginia. ReAlta was initially formed as a joint venture between Children’s Hospital of The King’s Daughters, Children’s Specialty Group and Eastern Virginia Medical School. ReAlta is dedicated to addressing life-threatening medical needs through beneficial inhibition of the Complement System and Inflammatory Mechanisms. To support this mission, ReAlta has developed a New Class of Drugs that can address unmet medical needs through unique Multi-Modal Therapeutic Capabilities.
For more information: https://realtalifesciences.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.